2025 AAHFN CEC Symposium - Facing the Challenges: Managing Hyperkalemia in Heart Failure Patients While Maintaining RAASi Therapy

HAZLET, N.J. - May 12, 2025 - PRLog -- Despite strong evidence for cardiorenal protective effects of RAASis, hyperkalemia (or fear of hyperkalemia) is a major driver of underuse and underdosing of RAASis in HF; these actions place HF patients at increased risk since dose reduction or discontinuation of RAASis is associated with worse outcomes in HF. Novel potassium binders effectively and safely lower serum potassium, potentially facilitating optimization of the use and dosing of RAASis. This symposium will include recent clinical evidence with potassium binders and a case discussion of roles and best practices of HF Nurses in managing hyperkalemia in their HF patients.

Click here for more information

CHAIR

Marie Galvao, MSN, ANP-BC, CHFN, HF-Cert
Lead Heart Failure Nurse Practitioner
Center for Advanced Cardiac Therapy
Montefiore Medical Center
Bronx, New York

FACULTY

Stephen Greene, MD
Associate Professor of Medicine
Duke University School of Medicine
Duke Clinical Research Institute
Durham, North Carolina

Lisa Rathman, MSN, CRNP, ACNP-BC, CHFN
Lead Nurse Practitioner
Heart Failure Section
Penn Medicine Lancaster General Health
Lancaster, Pennsylvania

Educational Objectives
- Explain the relationship between down-titration or discontinuation of RAASi therapy and clinical outcomes
- Interpret evidence from clinical trials of novel potassium binders for the treatment of hyperkalemia
- Identify HF patients who would benefit from potassium-lowering pharmacological therapy

Target Audience
This educational activity is intended for Heart Failure Nurses.

Educational Grant
AAHFN and Voxmedia International gratefully acknowledge the educational grant provided by AstraZeneca Pharmaceuticals.

Continuing Education Credits
AAHFN and Voxmedia International gratefully acknowledge the educational grant provided by AstraZeneca Pharmaceuticals.